Table 2.

OS and PFS Associated With KIR3DL1 and HLA-B Subtype Pairs Among Patients Who Received 3F8 for High-Risk Neuroblastoma

KIR3DL1/HLA-B Pairs	No.	Univariable Analysis				Multivariable Analysis*
		OS		PFS		OS		PFS
	OS/PFS	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Strong interacting	63/63	1		1		1		1
Weak interacting	55/55	0.89 (0.56 to 1.42)	.627	0.85 (0.55 to 1.30)	.450	0.55 (0.32 to 0.96)	.036	0.68 (0.40 to 1.15)	.153
Noninteracting	127/127	0.57 (0.38 to 0.85)	.007	0.56 (0.39 to 0.81)	.002	0.41 (0.25 to 0.65)	< .001	0.43 (0.28 to 0.66)	< .001

NOTE. Strong interacting: KIR3DL1-H + Bw4-80I or KIR3DL1-L + Bw4-80T; weak interacting: KIR3DL1-H + Bw4-80T or KIR3DL1-L + Bw4-80I; and noninteracting: KIR3DL1-N + any HLA-B, 3DS1 + any HLA-B, and Bw6 + any KIR3DL1.

Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

^*Adjusted for age, lactate dehydrogenase, granulocyte-macrophage colony-stimulating factor route (in OS only) and disease status at 3F8.